Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl


Preferences help
enabled [disable] Abstract
Number of results


2014 | 10 | 1 |

Article title

Effects of rivastigmine and memantine alone and
in combination on learning and memory in rats
with scopolamine-induced amnesia


Title variants

Languages of publication



Background: Cholinesterase inhibitors and glutamate
blockers are commonly used for the treatment of
cognitive impairment in Alzheimer’s disease. The aim
was to evaluate the effects of rivastigmine and memantine
alone or in combination in rats with scopolamine-impaired
memory. Method: 5 groups of rats were used: control, scopolamine
(model), model with rivastigmine, model with memantine,
and model with both drugs. Active avoidance test was performed
and the number of conditioned responses, unconditioned
responses and intertrial crossing were recorded.
Passive avoidance tests step-through with criteria latency
of reaction 180 s in the light chamber and step-down with
criteria latency of reaction 60 s on the platform were done. Results: Control rats learned the task and kept it on
memory tests. Scopolamine treated rats failed to perform
it. The rivastigmine, memantine and its combination
groups showed increased CRs during learning and
memory retention tests. In both passive avoidance tests
an increased latency of reaction was observed in the drug
treated groups. Conclusion: The combination of both drugs rivastigmine
and memantine is more effective than the use of the single
drug in cognitive impaired rats. Cholinesterase inhibitors
and NMDA blockers may be combined in the treatment of
different kind of dementias.








Physical description


1 - 4 - 2015
24 - 9 - 2015
7 - 7 - 2015


  • College of William and Mary, Williamsburg,
    Virginia 23187, USA
  • Department of Pharmacology and Clinical
    Pharmacology, Faculty of Medicine, Medical University, Plovdiv
    4002, Bulgaria
  • Department of Pharmacology, Medical Faculty, Medical University,
    15A V. Aprilov str, Plovdiv 4002, Bulgaria


  • ---
  • [1] Wilkinson D. Pharmacotherapy of Alzheimer’s disease. Alzheimer’s disease Psychiatry. 2005;4:43-47
  • [2] Kozhemyakin M, Rajasekaran K, Kapur J. Central cholinesterase inhibition enhances glutamate synaptic transmission. J Neurophysiology. 2010;103:1748-1757
  • [3] Chen Y, Evola M, Young AM. Memantine and dizocilpine interactions with antinociceptive or discriminative stimulus effects of morphine in rats after acute or chronic treatment with morphine. Psychopharmacology. 2013;225(1):187-199[WoS]
  • [4] Kaufman AM, Milnerwood AJ, Sepers MD, Coquinco A, She K, Wang L. Opposing roles of synaptic and extrasynaptic NMDA receptor signalling in cultured striatal and cortical neurons. J Neurosci. 2012;21(12):3992-4003[Crossref]
  • [5] Tariot PN, Farlow MR, Grossenberg GT. Memantine treatment in patients with moderate to severe Alzheimer’s disease. JAMA. 2004;291:317-324
  • [6] Battaglia F, Wang HY, Ghilardi MF, Gahi E, Quartarone A, Friedman E. Cortical plasticity in Alzheimer’s disease in humans and rodents. Biol Psychiatry. 2007;62:1405-1412[Crossref]
  • [7] Watt AJ, Syӧstrӧm PJ, Häusser M, Nelson SB, Turrigiano GG. A proportional but slower NMDA potentiation follows AMPA potentiation in LTP. Nat Neurosci. 2004;7:518-524[Crossref]
  • [8] Turrigiano GG, Nelson SB. Homeostatic plasticity in the developing nervous system. Nat Rev Neurosci. 2004;5:97-107[Crossref]
  • [9] Small GW, Bookheimer SY, Thompson PM, Cole GM, Huang SC, Kepe V. et al. Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol. 2008;7(2):161-172[Crossref][WoS]
  • [10] Watt AJ, van Rossum MC, MacLeod KM, Nelson SB, Turrigiano GG. Activity coregulates quantal AMPA and NMDA currents at neocortical synapses. Neuron. 2000;26:659-670[Crossref]
  • [11] Enz A, Gentsch C. C-administration of memantine has no effect in the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain. Neuropharmacology. 2004;47:408-413
  • [12] Csermansky JG, Martin M, Shah R, Bertchume A, Colvin J. Dong H. Cholinesterase inhibitors ameliorate behavioural deficits induced by MK-801 in mice. Neuropsychopharmacology. 2005;30:2135-2143[Crossref]
  • [13] Markram H, Segal M. Acetylcholine potentiates responses to NMDA receptors in the rat brain hippocampus. Neurosci Letters. 1990;113:62-65
  • [14] Mann EO, Greenfield SA. Novel modulatory mechanisms revealed by sustained application of nicotine in the guinea-pig hippocampus in vitro. J Physiol. 2003;551:539-550
  • [15] Miguel-Hidalgo JJ, Paul IA, Wanzo V, Banerjee PK. Memantine prevents cognitive impairment and reduces Bcl-2 and capsase 8 immunoreactivity in rats injected with amyloid β1-40. Eur J Pharmacol. 2012;692(5):38-45
  • [16] Tucci P, Mhillaj E, Morgese MG, Colaianna M, Zotti M, Schiavone S, et al. Memantine prevents memory consolidation failure induced by soluble beta amyloid in rats. Front Behav Neurosci. 2014;19(8):1-11[WoS]
  • [17] Jung JY, Roh M, Ko KK, Jang, HS, Lee SR, Ha JH. Effects of single treatment of anti-dementia drugs on sleep-wake patterns in rats. Korean J Physiol Pharmacol. 2012;16(4):231-236[WoS][Crossref]
  • [18] Anderiambeloson E, Huyard B, Poirand E, Wagner S. Methyllycacoinite- and scopolamine-induced cognitive dysfunction: differential reversal effect by conginition-enhancing drugs. Pharmacol Res Perspect. 2014;2(4):1-8
  • [19] Trebbastoni A, Gilio F, D’Antonio F, Cambieri C, Ceccanti M, de Lena C. Chronic treatment with rivastigmine in patients with Alzheimer’s disease: A study of primary motor cortex excitability tested by 5-Hz repetitive transcranial magnetic stimulation. Clinical Neurophysiology. 2012; 123:902-909
  • [20] Drever BD, Anderson WG, Johnson H, O’Callaghan M, Seo S, Choi DY. 2005. Memantine acts as a cholinergic stimulant in the mouse hippocampus. J Alzheimer’s Dis. 2005;2:319-333
  • [21] Busquet P, Capurro V, Cavalli A, Piomelli D, Reggiani A, Bertolelli R. Synergistic effects of galantamine and memantine in attenuating scopolamine-induced amnesia in mice. J Pharm Sci. 2012;20:305-309[Crossref]
  • [22] Wallace TL, Ballard TM, Pouzet B, Rieder WJ, Wettstein JG. Drug targets for cognitive enhacement in neuropsychiatric disorders. Pharmacol Biochem Behav. 2011;99:130-145

Document Type

Publication order reference


YADDA identifier

JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.